专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20070027192A1 Polysubstituted 1,1-pyridylamioncyclopropanamine compounds 失效
标题翻译：多取代的1,1-吡啶基氨基环丙胺化合物
公开(公告)号：US20070027192A1
公开(公告)日：2007-02-01
申请号：US11493155
申请日：2006-07-26
申请人： Solo Goldstein , Claude Guillonneau , Yves Charton , Brian Lockhart , Pierre Lestage
发明人： Solo Goldstein , Claude Guillonneau , Yves Charton , Brian Lockhart , Pierre Lestage
IPC分类号： A61K31/44 , C07D213/72
CPC分类号： C07D213/74
摘要： A compound selected from those of formula (I): wherein: n represents an integer from 1 to 6 inclusive, R1 and R2 represent a hydrogen atom, a (C1-C6)alkyl group or an aryl-(C1-C6)alkyl group, R3 and R4 represent a hydrogen atom or a (C1-C6)alkyl group, R5 and R6 represent a hydrogen atom or a (C1-C6)alkyl, halogen, hydroxy, (C1-C6)alkoxy, cyano, nitro, (C2-C6)acyl, (C1-C6)alkoxycarbonyl, (C1-C6)trihaloalkyl or (C1-C6)-trihaloalkoxy group or an optionally substituted amino group, R7 represents a hydrogen atom, a (C1-C6)alkyl group or an arylalkyl group, its enatiomers, diastereoisomers and additional salts thereof with a pharmaceutically acceptable acid or base. Medicinal products containing the same which are useful in the treatment of conditions requiring a specific nicotinic ligand of α4β2 receptors.
摘要翻译：选自式（I）的化合物：其中：n表示1至6的整数，其中R 1和R 2均表示氢原子，（C C 1 -C 6烷基或芳基 - （C 1 -C 6 -C 6）烷基，R R 3和R 4代表氢原子或（C 1 -C 6 -C 6）烷基， R 5和R 6表示氢原子或（C 1 -C 6 -C 6）烷基，卤素，羟基，（C 1 -C 6 -C 6）烷氧基，氰基，硝基，（C 2 -C 6 -C 6）酰基，（C 1 -C 6 -C 6）烷氧基羰基，（C 1 -C 6 -C 6）三卤代烷基或（C

2. 发明授权

US07388022B2 Polysubstituted 1,1-pyridylaminocyclopropanamine compounds 失效
标题翻译：多取代的1,1-吡啶基氨基环丙胺化合物
公开(公告)号：US07388022B2
公开(公告)日：2008-06-17
申请号：US11493155
申请日：2006-07-26
申请人： Solo Goldstein , Claude Guillonneau , Yves Charton , Brian Lockhart , Pierre Lestage
发明人： Solo Goldstein , Claude Guillonneau , Yves Charton , Brian Lockhart , Pierre Lestage
IPC分类号： C07D213/74 , A61K31/44
CPC分类号： C07D213/74
摘要： A compound selected from those of formula (I): wherein: n represents an integer from 1 to 6 inclusive, R1 and R2 represent a hydrogen atom, a (C1-C6)alkyl group or an aryl-(C1-C6)alkyl group, R3 and R4 represent a hydrogen atom or a (C1-C6)alkyl group, R5 and R6 represent a hydrogen atom or a (C1-C6)alkyl, halogen, hydroxy, (C1-C6)alkoxy, cyano, nitro, (C2-C6)acyl, (C1-C6)alkoxycarbonyl, (C1-C6)trihaloalkyl or (C1-C6)-trihaloalkoxy group or an optionally substituted amino group, R7 represents a hydrogen atom, a (C1-C6)alkyl group or an arylalkyl group, its enatiomers, diastereoisomers and additional salts thereof with a pharmaceutically acceptable acid or base. Medicinal products containing the same which are useful in the treatment of conditions requiring a specific nicotinic ligand of α4β2 receptors.
摘要翻译：选自式（I）的化合物：其中：n表示1至6的整数，其中R 1和R 2均表示氢原子，（C C 1 -C 6烷基或芳基 - （C 1 -C 6 -C 6）烷基，R R 3和R 4代表氢原子或（C 1 -C 6 -C 6）烷基， R 5和R 6表示氢原子或（C 1 -C 6 -C 6）烷基，卤素，羟基，（C 1 -C 6 -C 6）烷氧基，氰基，硝基，（C 2 -C 6 -C 6）酰基，（C 1 -C 6 -C 6）烷氧基羰基，（C 1 -C 6 -C 6）三卤代烷基或（C

3. 发明授权

US07348344B2 Polysubstituted 1,1-pyridyloxycyclopropanamine compounds 失效
标题翻译：多取代的1,1-吡啶氧基环丙胺化合物
公开(公告)号：US07348344B2
公开(公告)日：2008-03-25
申请号：US11493070
申请日：2006-07-26
申请人： Solo Goldstein , Claude Guillonneau , Yves Charton , Brian Lockhart , Pierre Lestage
发明人： Solo Goldstein , Claude Guillonneau , Yves Charton , Brian Lockhart , Pierre Lestage
IPC分类号： C07D213/70 , A61K31/4412
CPC分类号： C07D213/65
摘要： A compound selected from those of formula (I): wherein: n represents an integer from 1 to 6 inclusive, R1 and R2 represent a hydrogen atom, a (C1-C6)alkyl group or an aryl-(C1-C6)alkyl group, R3 and R4 represent a hydrogen atom or a (C1-C6)alkyl group, R5 and R6 represent a hydrogen atom, or a (C1-C6)alkyl, halogen, hydroxy, (C1-C6)alkoxy, cyano, nitro, (C2-C6)acyl, (C1-C6)alkoxycarbonyl, (C1-C6)trihaloalkyl, (C1-C6)trihaloalkoxy or optionally substituted amino group, its enantiomers, diastereoisomers and additional salts thereof with a pharmaceutically acceptable acid or base. Medicinal products containing the same which are useful in the treatment of conditions requiring a specific nicotinic ligand of α4β2 receptors.
摘要翻译：选自式（I）的化合物：其中：n表示1至6的整数，其中R 1和R 2均表示氢原子，（C C 1 -C 6烷基或芳基 - （C 1 -C 6 -C 6）烷基，R R 3和R 4代表氢原子或（C 1 -C 6 -C 6）烷基， R 5和R 6表示氢原子或（C 1 -C 6 -C 6）烷基，卤素，羟基（C 1 -C 6），（C 1 -C 6 -C 6）烷氧基，氰基，硝基，（C 2 -C 6 -C 6）酰基（C 1 -C 6 -C 6）烷氧基羰基，（C 1 -C 6 -C 6）三卤代烷基，（C 1 -C 6 - 三卤代烷氧基或任选取代的氨基，其对映异构体，非对映异构体及其药学上可接受的酸或碱的其它盐。含有该药物的药物可用于治疗需要α4β2受体特异性烟碱配体的病症。

4. 发明授权

US06943184B2 1,1- and 1,2-disubstituted cyclopropane compounds 失效
标题翻译： 1,1-和1,2-二取代环丙烷化合物
公开(公告)号：US06943184B2
公开(公告)日：2005-09-13
申请号：US09888990
申请日：2001-06-26
申请人： Solo Goldstein , Claude Guillonneau , Yves Charton , Brian Lockhart , Pierre Lestage
发明人： Solo Goldstein , Claude Guillonneau , Yves Charton , Brian Lockhart , Pierre Lestage
IPC分类号： C07D295/08 , A61K31/10 , A61K31/13 , A61K31/133 , A61K31/15 , A61K31/16 , A61K31/215 , A61K31/22 , A61K31/221 , A61K31/223 , A61K31/27 , A61K31/40 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/445 , A61K31/455 , A61P25/00 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/20 , A61P25/24 , A61P25/28 , A61P25/34 , A61P29/00 , A61P29/02 , A61P43/00 , C07C62/02 , C07C209/00 , C07C211/37 , C07C213/00 , C07C213/02 , C07C213/06 , C07C215/20 , C07C215/42 , C07C217/44 , C07C217/52 , C07C219/18 , C07C219/20 , C07C219/24 , C07C269/00 , C07C269/02 , C07C271/12 , C07C271/22 , C07C271/24 , C07C271/34 , C07C319/14 , C07C321/28 , C07C323/26 , C07C323/33 , C07D213/30 , C07D213/38 , C07D213/53 , C07D213/65 , C07D213/70 , C07D213/80 , C07D213/803 , C07D295/096 , C07D417/12 , C07D213/00
CPC分类号： C07D213/70 , C07C217/44 , C07C217/52 , C07C219/18 , C07C219/24 , C07C271/12 , C07C271/34 , C07C323/26 , C07C2601/02 , C07D213/65 , C07D295/096
摘要： A compound selected from those of formula (I): wherein: p represents an integer of from 0 to 6 inclusive, n represents an integer of from 0 to 6 inclusive, R1, and R2 represent a group selected from hydrogen, alkyl, aryl and arylalkyl, or R1+R2 form together with nitrogen carrying them saturated, monocyclic, or bicyclic system, X represents a group selected from oxygen, sulphur, a group —CH═CH—, methylene, a group of formula —HC═N—O— and a group of formula —O—CH2—CH═CH—, in which groups oxygen is linked to Y of the compounds of formula (I), Y represents a group selected from aryl, heteroaryl, arylalkyl, heteroarylalkyl, —C(O)-A, and —C(S)-A, A represents a group selected from alkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, and NR3R4 wherein R3, and R4 represent a group selected from hydrogen, alkyl, aryl, and arylalkyl, or R3+R4 form together with nitrogen carrying them monocyclic, or bicyclic (C3-C10) system, its isomers and addition salts thereof with a pharmaceutically-acceptable acid or base, and medicinal products containing the same which are useful as specific nicotinic ligand of α4β2 receptors.
摘要翻译：选自式（I）的化合物：其中：p表示0〜6的整数，n表示0以上6以下的整数，R 1，R 2， 2表示选自氢，烷基，芳基和芳烷基或R 1 + R 2 2 +的基团与携带它们饱和，单环或双环的氮系统中，X表示选自氧，硫，基团-CH-CH-，亚甲基，式-HC-NO-基团和式-O-CH 2 -CH-基团的基团 -CH-，其中氧与式（I）化合物的Y连接，Y表示选自芳基，杂芳基，芳烷基，杂芳基烷基，-C（O）-A和-C（S） - A，A表示选自烷基，芳基，杂芳基，芳基烷基，杂芳基烷基和NR 3 R 4中的基团，其中R 3和R 3 代表选自氢，烷基，芳基和芳基烷基或R 3 + R 4 +的化合物与氮气携带其单环或双环（C 3 -C 10）系统，其异构体和与药学上可接受的酸或碱的加成盐，以及含有它们的药物其可用作α4β2受体的特异性烟碱配体。

5. 发明授权

US5348956A Substituted cyclopropylamino-1,3,5-triazines 失效
标题翻译：取代的环丙基氨基-1,3,5-三嗪
公开(公告)号：US5348956A
公开(公告)日：1994-09-20
申请号：US103119
申请日：1993-08-09
申请人： Berend J. Van Keulen , Solo Goldstein , Eric Cossement , Jean Gobert , Ernst Wulfert
发明人： Berend J. Van Keulen , Solo Goldstein , Eric Cossement , Jean Gobert , Ernst Wulfert
IPC分类号： A61K31/53 , A61K31/5377 , A61K31/541 , A61P11/00 , A61P11/06 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/26 , A61P25/28 , A61P29/00 , C07D251/12 , C07D251/14 , C07D251/16 , C07D251/18 , C07D251/22 , C07D401/04 , C07D403/04 , C07D411/04 , C07D413/04 , C07D417/04 , C07D498/08 , A61K31/535
CPC分类号： C07D401/04 , C07D251/18 , C07D411/04 , C07D417/04 , Y10S514/826 , Y10S514/886
摘要： New substituted cyclopropylamino-1,3,5-triazines having the formula ##STR1## wherein R.sub.1 is C.sub.1 -C.sub.3 -alkyl, C.sub.3 -C.sub.5 -cycloalkyl or C.sub.1 -C.sub.3 -alkyl-C.sub.3 -C.sub.5 -cycloalkylR.sub.2 is bis(2-hydroxyethyl)amino, 3-hydroxy-1-azetidinyl, 3-methoxy-1-azetidinyl, 3-oxo-1-azetidinyl, morpholino, 4-hydroxypiperidino, thiomorpholino, thiomorpholino S-oxide, thiomorpholino S,S-dioxide, 3-thiazolidinyl, 3-thiazolidinyl S-oxide, 3-thiazolidinyl S,S-dioxide or 8-oxa-3-azabicyclo[3,2,1]oct-3-yl. Processes for the preparation thereof and pharmaceutical composition containing them are also given. The compounds are useful for the treatment of inflammation and asthma.
摘要翻译：具有式（I）的新的取代的环丙基氨基-1,3,5-三嗪其中R1是C1-C3-烷基，C3-C5-环烷基或C1-C3-烷基-C3-C5-环烷基R2是双 2-羟乙基）氨基，3-羟基-1-氮杂环丁烷基，3-甲氧基-1-氮杂环丁烷基，3-氧代-1-氮杂环丁烷基，吗啉代，4-羟基哌啶子基，硫代吗啉代，硫代吗啉代S-氧化物，硫代吗啉代S，S-二氧化物， 3-噻唑烷基，3-噻唑烷基S-氧化物，3-噻唑烷基S，S-二氧化物或8-氧杂-3-氮杂双环[3,2,1]辛-3-基。还给出了其制备方法和含有它们的药物组合物。该化合物可用于治疗炎症和哮喘。

6. 发明申请

US20070027191A1 Polysubstituted 1,1-pyridyloxycyclopropanamine compounds 失效
标题翻译：多取代的1,1-吡啶氧基环丙胺化合物
公开(公告)号：US20070027191A1
公开(公告)日：2007-02-01
申请号：US11493070
申请日：2006-07-26
申请人： Solo Goldstein , Claude Guillonneau , Yves Charton , Brian Lockhart , Pierre Lestage
发明人： Solo Goldstein , Claude Guillonneau , Yves Charton , Brian Lockhart , Pierre Lestage
IPC分类号： A61K31/4412 , C07D213/70
CPC分类号： C07D213/65
摘要： A compound selected from those of formula (I): wherein: n represents an integer from 1 to 6 inclusive, R1 and R2 represent a hydrogen atom, a (C1-C6)alkyl group or an aryl-(C1-C6)alkyl group, R3 and R4 represent a hydrogen atom or a (C1-C6)alkyl group, R5 and R6 represent a hydrogen atom, or a (C1-C6)alkyl, halogen, hydroxy, (C1-C6)alkoxy, cyano, nitro, (C2-C6)acyl, (C1-C6)alkoxycarbonyl, (C1-C6)trihaloalkyl, (C1-C6)trihaloalkoxy or optionally substituted amino group, its enantiomers, diastereoisomers and additional salts thereof with a pharmaceutically acceptable acid or base. Medicinal products containing the same which are useful in the treatment of conditions requiring a specific nicotinic ligand of α4β2 receptors.
摘要翻译：选自式（I）的化合物：其中：n表示1至6的整数，其中R 1和R 2均表示氢原子，（C C 1 -C 6烷基或芳基 - （C 1 -C 6 -C 6）烷基，R R 3和R 4代表氢原子或（C 1 -C 6 -C 6）烷基， R 5和R 6表示氢原子或（C 1 -C 6 -C 6）烷基，卤素，羟基（C 1 -C 6），（C 1 -C 6 -C 6）烷氧基，氰基，硝基，（C 2 -C 6 -C 6）酰基（C 1 -C 6 -C 6）烷氧基羰基，（C 1 -C 6 -C 6）三卤代烷基，（C 1 -C 6 - 三卤代烷氧基或任选取代的氨基，其对映异构体，非对映异构体及其药学上可接受的酸或碱的其它盐。含有该药物的药物可用于治疗需要α4β2受体特异性烟碱配体的病症。

7. 发明授权

US06992085B2 Octahydro-2H-pyrido[1,2-a]pyrazine compounds 失效
标题翻译：八氢-2H-吡啶并[1,2-a]吡嗪化合物
公开(公告)号：US06992085B2
公开(公告)日：2006-01-31
申请号：US10195019
申请日：2002-07-12
申请人： Solo Goldstein , Guillaume Poissonnet , Jean-Gilles Parmentier , Pierre Lestage , Brian Lockhart
发明人： Solo Goldstein , Guillaume Poissonnet , Jean-Gilles Parmentier , Pierre Lestage , Brian Lockhart
IPC分类号： A61K31/4985 , C07D471/04
CPC分类号： C07D471/04
摘要： A compound selected from those of formula (I): wherein: Ra represents linear or branched (C1–C6)alkylene, X represents a group selected from W1, —C(W1)—W2—, —W2—C(W1)—, —W2—C(W1)W2—, —W2—Ra— and —CH(OR1)— wherein W1, W2 and R1 are as defined in the description, when Y represents aryl or heteroaryl, or X represents a group selected from single bond, —C(W1)—, —W2—C(W1)—, —W2—Ra and —CH(OR1)— wherein W1, W2, Ra and R1 are as defined hereinbefore, when Y represents a fused bicyclic group, of formula: wherein: A represents nitrogen-containing heterocycle having from 4 to 7 ring members that is unsaturated or partially saturated and optionally contains a second hetero atom, B represents phenyl ring optionally substituted by one or more groups as defined in the description, its isomers, and addition salts thereof with a pharmaceutically acceptable acid or base, medicinal products containing the same are useful in the treatment of cognitive deficiencies.
摘要翻译：选自式（I）的化合物：其中：R a表示直链或支链（C 1 -C 6 -C 6）亚烷基，X表示选自W SUB -C（W 1） - W 2 - ， - W 2 -C（W 1）） - ，-W 2 -C（W 1）W 2 - ， - W 2

8. 发明授权

US06916797B2 α-arylethylpiperazine derivatives as neurokinin antagonists 失效
标题翻译： α-苯乙基哌嗪衍生物作为神经激肽拮抗剂
公开(公告)号：US06916797B2
公开(公告)日：2005-07-12
申请号：US10168331
申请日：2000-12-14
申请人： Françoise Stiernet , Christophe Genicot , Marie-Agnes Lassoie , Florence Moureau , Thomas Ryckmans , Thierry Taverne , Jean-Pierre Henichart , Michel Neuwels , Solo Goldstein
发明人： Françoise Stiernet , Christophe Genicot , Marie-Agnes Lassoie , Florence Moureau , Thomas Ryckmans , Thierry Taverne , Jean-Pierre Henichart , Michel Neuwels , Solo Goldstein
IPC分类号： C07D249/08 , A61K31/495 , A61K31/496 , A61K31/5375 , A61K31/662 , A61P11/02 , A61P11/06 , A61P29/00 , A61P37/08 , A61P43/00 , C07D209/34 , C07D209/48 , C07D213/36 , C07D213/38 , C07D257/04 , C07D295/08 , C07D295/088 , C07D295/13 , C07D295/15 , C07D307/52 , C07D307/87 , C07D333/20 , C07D333/72 , C07F9/6509 , C07D295/155
CPC分类号： C07D295/088 , C07D295/13 , C07D295/15
摘要： The invention relates to new α-arylethylpiperazine of the formula wherein Z represents 0 or S; n′ represents 1 or 2; R2 represents a hydrogen atom or a methyl group; W, Ar1 and Ar2 represent various substituents as defined herein; or non-toxic pharmaceutically acceptable salt, individual optical isomer, or individual diastereoisomer thereof, which are useful as neurokinin receptor antagonists (NK1 antagonists). It also relates to processes for their preparation and use in methods for treatment of asthma and/or allergic rhinitis.
摘要翻译：本发明涉及下式的新的α-芳基乙基哌嗪：其中Z代表0或S; n'表示1或2; R 2表示氢原子或甲基; W，Ar 1和Ar 2表示本文定义的各种取代基; 或无毒的药学上可接受的盐，单独的光学异构体或其各自的非对映异构体，其可用作神经激肽受体拮抗剂（NK 1拮抗剂）。它还涉及其制备和用于治疗哮喘和/或过敏性鼻炎的方法的方法。

9. 发明申请

US20050032845A1 1,1-and 1,2-disubstituted cyclopropane compounds 审中-公开
标题翻译： 1,1和1,2-二取代的环丙烷化合物
公开(公告)号：US20050032845A1
公开(公告)日：2005-02-10
申请号：US10929928
申请日：2004-08-30
申请人： Solo Goldstein , Claude Guillonneau , Yves Charton , Brian Lockhart , Pierre Lestage
发明人： Solo Goldstein , Claude Guillonneau , Yves Charton , Brian Lockhart , Pierre Lestage
IPC分类号： C07D295/08 , A61K31/10 , A61K31/13 , A61K31/133 , A61K31/15 , A61K31/16 , A61K31/215 , A61K31/22 , A61K31/221 , A61K31/223 , A61K31/27 , A61K31/40 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/445 , A61K31/455 , A61P25/00 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/20 , A61P25/24 , A61P25/28 , A61P25/34 , A61P29/00 , A61P29/02 , A61P43/00 , C07C62/02 , C07C209/00 , C07C211/37 , C07C213/00 , C07C213/02 , C07C213/06 , C07C215/20 , C07C215/42 , C07C217/44 , C07C217/52 , C07C219/18 , C07C219/20 , C07C219/24 , C07C269/00 , C07C269/02 , C07C271/12 , C07C271/22 , C07C271/24 , C07C271/34 , C07C319/14 , C07C321/28 , C07C323/26 , C07C323/33 , C07D213/30 , C07D213/38 , C07D213/53 , C07D213/65 , C07D213/70 , C07D213/80 , C07D213/803 , C07D295/096 , C07D417/12
CPC分类号： C07D213/70 , C07C217/44 , C07C217/52 , C07C219/18 , C07C219/24 , C07C271/12 , C07C271/34 , C07C323/26 , C07C2601/02 , C07D213/65 , C07D295/096
摘要： A compound selected from those of formula (1): wherein: p represents an integer of from 0 to 6 inclusive, n represents an integer of from 0 to 6 inclusive, R1, and R2 represent a group selected from hydrogen, alkyl, aryl and arylalkyl, or R1+R2 form together with nitrogen carrying them saturated, monocyclic, or bicyclic system, X represents a group selected from oxygen, sulphur, a group —CH═CH—, methylene, a group of formula —HC═N—O— and a group of formula —O—CH2—CH═CH—, in which groups oxygen is linked to Y of the compounds of formula (I), Y represents a group selected from aryl, heteroaryl, arylalkyl, heteroarylalkyl, —C(O)-A, and —C(S)-A, A represents a group selected from alkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, and NR3R4 wherein R3, and R4 represent a group selected from hydrogen, alkyl, aryl, and arylalkyl, or R3+R4 form together with nitrogen carrying them monocyclic, or bicyclic (C3-C10) system, its isomers and addition salts thereof with a pharmaceutically-acceptable acid or base, and medicinal products containing the same are useful as specific nicotinic ligand of α4β2 receptors.
摘要翻译：选自式（1）的化合物：其中：p表示0〜6的整数，n表示0〜6的整数，R1，R2表示选自氢，烷基，芳基和芳基烷基或R 1 + R 2与带有饱和，单环或双环体系的氮一起形成，X表示选自氧，硫，基团-CH = CH-，亚甲基，式-HC = NO-的基团和式-O-CH2-CH = CH-的基团，其中氧与式（I）化合物的Y连接，Y表示选自芳基，杂芳基，芳烷基，杂芳基烷基，-C（O） -A和-C（S）-A，A表示选自烷基，芳基，杂芳基，芳基烷基，杂芳基烷基和NR 3 R 4中的基团，其中R 3，R 4表示选自氢，烷基，芳基和芳烷基的基团，或 R3 + R4与携带它们单环或二环（C 3 -C 10）体系的氮一起形成，其异构体及其加成盐与药学上可接受的酸或碱，以及含有它们的药物可用作α4β2受体的特异性烟碱配体。

10. 发明授权

US06350757B1 Beta-carboline compounds 失效
标题翻译： β-咔啉化合物
公开(公告)号：US06350757B1
公开(公告)日：2002-02-26
申请号：US09621742
申请日：2000-07-21
申请人： Solo Goldstein , Guillaume Poissonnet , Jean-Gilles Parmentier , Jean-Daniel Brion , Mark Millan , Anne Dekeyne , Jean Boutin
发明人： Solo Goldstein , Guillaume Poissonnet , Jean-Gilles Parmentier , Jean-Daniel Brion , Mark Millan , Anne Dekeyne , Jean Boutin
IPC分类号： C07D47114
CPC分类号： C07D471/04
摘要： A compound selected from those of formula (I): wherein: represents single or double bond, R1 represents hydrogen, alkyl, —R6-aryl, —R6-cycloalkyl, —R6-heterocycle, —CO2R7—, —COR8, or —CONHR8, wherein R6, R7, and R8 are as defined in the description, R2 represents cyano, mono- or di-alkylaminoalkylaminocarbonyl, —CO2R8, —CONHR8, —NR8R9, —NHCO2R7, or —COR8 wherein R7, R8, and R9 are as defined in the description, R3 and R4 together form (C3-C10)cycloalkyl, R5 represents hydrogen, alkyl, or arylalkyl, Ra, Rb, Rc, Rd, which may be identical or different, represent a group as defined in the description, its isomers, and pharmaceutically-acceptable acid or base addition salts thereof, and medicinal products containing the same which are useful in the treatment of CNS disorders.
摘要翻译：选自式（I）的化合物：其中：CUSTOM-CHARACTER FILE =“US06350757-20020226-P00900.TIF”ID =“CUSTOM-CHARACTER-00001”>表示单键或双键，R1表示氢，烷基， -R6-芳基，-R6-环烷基，-R6-杂环，-CO2R7-，-COR8或-CONHR8，其中R6，R7和R8如说明书中所定义，R 2表示氰基，单或二烷基氨基烷基氨基羰基，-CO 2 R 8，-CONHR 8，-NR 8 R 9，-NHCO 2 R 7或-COR 8，其中R 7，R 8和R 9如说明书中所定义，R 3和R 4一起形成（C 3 -C 10）环烷基，R 5表示氢，烷基或芳烷基可以相同或不同的R a，R b，R c，R d表示本说明书中定义的基团，其异构体及其药学上可接受的酸或碱加成盐，以及含有该基团的药物，其可用于治疗中枢神经系统疾病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式